glp 1 analogue market GLP-1 Analogues Size, Trends, Growth Report 2032 Global GLP-1 Receptor Agonist Market
Description
Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: insights from the SUSTAIN 1-7 trials
Hunger is not just a nuisance
For example, in the SUSTAIN 5 clinical trial, patients with HbA1c levels of 8.0% or lower had their basal insulin doses reduced by 20% when starting semaglutide therapy to minimize the risk of low blood sugar
3.5 years) and rate of treatment discontinuation [13]
Individuals who received Wegovy lost an average of 12.4% of their initial body weight compared to individuals who received a placebo
